柳氮磺吡啶肠溶片人体生物等效性研究

梁燕; 王凌; 王蕊; 常臻; 钟延强; 邹豪

doi:10.3969/j.issn.1006-0111.2013.06.007

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

柳氮磺吡啶肠溶片人体生物等效性研究

梁燕, 王凌, 王蕊, 常臻, 钟延强, 邹豪

文章导航 > 药学实践与服务 > 2013 > 31(6): 424-427,466

梁燕, 王凌, 王蕊, 常臻, 钟延强, 邹豪. 柳氮磺吡啶肠溶片人体生物等效性研究[J]. 药学实践与服务, 2013, 31(6): 424-427,466. doi: 10.3969/j.issn.1006-0111.2013.06.007

引用本文:

梁燕, 王凌, 王蕊, 常臻, 钟延强, 邹豪. 柳氮磺吡啶肠溶片人体生物等效性研究[J]. 药学实践与服务, 2013, 31(6): 424-427,466. doi: 10.3969/j.issn.1006-0111.2013.06.007

LIANG Yan, WANG Ling, WANG Rui, CHANG Zhen, ZHONG Yan-qiang, ZOU Hao. Study on bioequivalence of sulfasalazine enteric-coated tablet in healthy volunteers[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(6): 424-427,466. doi: 10.3969/j.issn.1006-0111.2013.06.007

Citation:

LIANG Yan, WANG Ling, WANG Rui, CHANG Zhen, ZHONG Yan-qiang, ZOU Hao. Study on bioequivalence of sulfasalazine enteric-coated tablet in healthy volunteers[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(6): 424-427,466. doi: 10.3969/j.issn.1006-0111.2013.06.007

柳氮磺吡啶肠溶片人体生物等效性研究

doi: 10.3969/j.issn.1006-0111.2013.06.007

梁燕¹,
王凌²,
王蕊³,
常臻³,
钟延强¹,
邹豪^1,

1.
第二军医大学药学院药剂学教研室, 上海 200433
2.
四川大学华西药学院, 成都 610041
3.
上海信谊药厂有限公司药物研究所, 上海 201206

Study on bioequivalence of sulfasalazine enteric-coated tablet in healthy volunteers

1.
Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
2.
Huaxi School of Pharmacy, Sichuan University, Chengdu 610041, China
3.
Institute of Drug Research, Shanghai Xinyi Pharmaceutical Co., Ltd. Shanghai 201206, China

摘要: 目的柳氮磺吡啶肠溶片(sulfasalazine enteric-coated tablet,SECT)属于口服不易吸收的药物,其人体药动学和相对生物利用度研究存在一定难度。本研究通过评价不同厂家生产的两种制剂的生物等效性,建立SECT的研究方法。方法对24名健康男性志愿者按随机交叉自身对照的方法,给予单剂量口服500 mg SECT受试制剂和参比制剂,两次试验间隔为1周,分别测定血浆柳氮磺吡啶(sulfasalazine,SS)、磺胺吡啶(sulfapyridine,SP)、5-氨基水杨酸(5-aminosalicylic acid,5-ASA)浓度。结果血浆中SS、SP、5-ASA的药动学参数如下:以AUC_0→t计算,受试制剂SECT中SS相对生物利用度为(108.8±24.1)%;SP相对生物利用度为(105.0±25.0)%;5-ASA相对生物利用度为(94.1±22.0)%。以AUC_0→∞计算,受试制剂SECT中SS相对生物利用度为(106.9±23.4)%;SP相对生物利用度为(104.1±25.0)%;5-ASA相对生物利用度为(93.6±22.2)%。受试制剂与参比制剂的血药浓度-时间曲线基本一致,受试制剂与参比制剂主要药动学参数无显著性差异(P>0.05)。结论两家厂家生产的SECT,受试制剂与参比制剂在健康中国人体内具有生物等效性。
- 柳氮磺吡啶 /
- 磺胺吡啶 /
- 5-氨基水杨酸 /
- 生物等效性
Abstract: Objective To evaluate the pharmacokinetics and relative bioavailability of sulfasalazine enteric-coated tablets from two different factories in healthy volunteers. Methods 24 healthy male volunteers were enrolled in the study.A single oral dose(500 mg) of test and reference Sulfasalazine Enteric-coated tablet preparations were given respectively to the volunteers according to randomized two way cross over study design.The washout period was l week.The plasma concentrations of Sulfasalazine(SASP)and sulfapyridine(SP)were determined by HPLC-UV method, the plasma concentrations of 5-aminosalicylic acid(5-ASA) were determined by HPLC-FLU method. Results The pharmacokinetic parameters of SASP, SP and 5-ASA in plasma were as follows:according to AUC_0→t, the relative bioavailability of SASP、SP and 5-ASA was (108.8±24.1)%, (105.0±25.0)% and (94.1±22.0)% in the test preparations; while according to AUC_0→∞, the relative bioavailability of SASP、SP and 5-ASA was (106.9±23.4)%, (104.1±25.0)% and (93.6±22.2)% in the test preparations. Mean plasma concentration-time curve of the test product was highly close to that of the reference product.There was no significant difference in pharmacokinetic parameters between the test and reference preparations of sulfasalazine enteric-coated tablets (P>0.05). Conclusion The results of statistical analysis showed that the two sulfasalazine enteric-coated tablets from different factories in healthy volunteers were bioequivalent.
- sulfasalazine(SASP) /
- sulfapyridine(SP) /
- 5-aminosalicylic acid(5-ASA) /
- pharmacokinetics and relative bioavailability

[1]	CDER/FDA. Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, March 2003.http://www.fda.gov/downloads/Drugs/Guidance Compliance Regulatory Information/Guidances/UCM070124.pdf.
[2]	FDA. Draft Guidance on Sulfasalazine,Feb 2010.http://www.fda.gov/downloads/Drugs/Guidance_Compliance_Regulatory_Information/Guidances/UCM199673.pdf.
[3]	李金恒,刘存刚,姚旋,等.HPLC梯度洗脱法测定血浆中柳氮磺吡啶及其代谢物[J].医学研究生学报, 2008, 7(21):682.
[4]	白小红,胡爽,李进霞,等.高效液相色谱法测定人血浆中柳氮磺胺吡啶及其代谢物[J].中国医院药学杂志,2004,24(4):208.
[5]	Ma JJ,Liu CG,Li JH,et al. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population[J].Clin Chem Acta,2009,407:30.
[6]	Gu GZ,Xia HM,Pang ZQ,et al.Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromategraphy/tandem mass spectrometry and its application to a pharmacokinetic study[J].J Chromtog B,2011,879:449.

[1]	陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠. UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(8): 341-345. doi: 10.12206/j.issn.2097-2024.202404082
[2]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
[3]	杨嘉宁, 赵一颖, 肖伟. 七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
[4]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[5]	戴菲菲, 傅翔, 陈琼年, 俞苏纯. 上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
[6]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[7]	陈炳辰, 王思真, 郭贝贝, 杨峰. 紫杉醇棕榈酸酯的合成及其脂质体的制备与处方研究 . 药学实践与服务, 2024, 42(9): 379-384, 410. doi: 10.12206/j.issn.2097-2024.202404062
[8]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[9]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[10]	陈方剑, 骆锦前, 王志君, 胡叶帅, 孙煜昕, 宋洪杰. HPLC-MS/MS同时测定感冒安颗粒中5种黄酮成分的含量 . 药学实践与服务, 2024, 42(9): 402-406. doi: 10.12206/j.issn.2097-2024.202403030
[11]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2024, 42(12): 1-8. doi: 10.12206/j.issn.2097-2024.202312027
[12]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[13]	张林晨, 张小琴, 张俊平. 山楂酸药理作用的研究进展 . 药学实践与服务, 2024, 42(5): 185-189. doi: 10.12206/j.issn.2097-2024.202307052
[14]	景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞. 黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
[15]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[16]	王耀振, 徐灿, 吕顺莉, 田泾, 张东炜. 钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
[17]	杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛. 正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
[18]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062

点击查看大图

计量

文章访问数: 3553
HTML全文浏览量: 373
PDF下载量: 221
被引次数: 0

柳氮磺吡啶肠溶片人体生物等效性研究

doi: 10.3969/j.issn.1006-0111.2013.06.007

1. 第二军医大学药学院药剂学教研室, 上海 200433

2. 四川大学华西药学院, 成都 610041

3. 上海信谊药厂有限公司药物研究所, 上海 201206

收稿日期: 2013-03-25
修回日期: 2013-05-15

关键词:

摘要: 目的柳氮磺吡啶肠溶片(sulfasalazine enteric-coated tablet,SECT)属于口服不易吸收的药物,其人体药动学和相对生物利用度研究存在一定难度。本研究通过评价不同厂家生产的两种制剂的生物等效性,建立SECT的研究方法。方法对24名健康男性志愿者按随机交叉自身对照的方法,给予单剂量口服500 mg SECT受试制剂和参比制剂,两次试验间隔为1周,分别测定血浆柳氮磺吡啶(sulfasalazine,SS)、磺胺吡啶(sulfapyridine,SP)、5-氨基水杨酸(5-aminosalicylic acid,5-ASA)浓度。结果血浆中SS、SP、5-ASA的药动学参数如下:以AUC_0→t计算,受试制剂SECT中SS相对生物利用度为(108.8±24.1)%;SP相对生物利用度为(105.0±25.0)%;5-ASA相对生物利用度为(94.1±22.0)%。以AUC_0→∞计算,受试制剂SECT中SS相对生物利用度为(106.9±23.4)%;SP相对生物利用度为(104.1±25.0)%;5-ASA相对生物利用度为(93.6±22.2)%。受试制剂与参比制剂的血药浓度-时间曲线基本一致,受试制剂与参比制剂主要药动学参数无显著性差异(P>0.05)。结论两家厂家生产的SECT,受试制剂与参比制剂在健康中国人体内具有生物等效性。

English Abstract

Study on bioequivalence of sulfasalazine enteric-coated tablet in healthy volunteers

1. Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

2. Huaxi School of Pharmacy, Sichuan University, Chengdu 610041, China

3. Institute of Drug Research, Shanghai Xinyi Pharmaceutical Co., Ltd. Shanghai 201206, China

Received Date: 2013-03-25
Rev Recd Date: 2013-05-15

Keywords:

sulfasalazine(SASP) /
sulfapyridine(SP) /
5-aminosalicylic acid(5-ASA) /
pharmacokinetics and relative bioavailability

Abstract: Objective To evaluate the pharmacokinetics and relative bioavailability of sulfasalazine enteric-coated tablets from two different factories in healthy volunteers. Methods 24 healthy male volunteers were enrolled in the study.A single oral dose(500 mg) of test and reference Sulfasalazine Enteric-coated tablet preparations were given respectively to the volunteers according to randomized two way cross over study design.The washout period was l week.The plasma concentrations of Sulfasalazine(SASP)and sulfapyridine(SP)were determined by HPLC-UV method, the plasma concentrations of 5-aminosalicylic acid(5-ASA) were determined by HPLC-FLU method. Results The pharmacokinetic parameters of SASP, SP and 5-ASA in plasma were as follows:according to AUC_0→t, the relative bioavailability of SASP、SP and 5-ASA was (108.8±24.1)%, (105.0±25.0)% and (94.1±22.0)% in the test preparations; while according to AUC_0→∞, the relative bioavailability of SASP、SP and 5-ASA was (106.9±23.4)%, (104.1±25.0)% and (93.6±22.2)% in the test preparations. Mean plasma concentration-time curve of the test product was highly close to that of the reference product.There was no significant difference in pharmacokinetic parameters between the test and reference preparations of sulfasalazine enteric-coated tablets (P>0.05). Conclusion The results of statistical analysis showed that the two sulfasalazine enteric-coated tablets from different factories in healthy volunteers were bioequivalent.

梁燕, 王凌, 王蕊, 常臻, 钟延强, 邹豪. 柳氮磺吡啶肠溶片人体生物等效性研究[J]. 药学实践与服务, 2013, 31(6): 424-427,466. doi: 10.3969/j.issn.1006-0111.2013.06.007

引用本文:

梁燕, 王凌, 王蕊, 常臻, 钟延强, 邹豪. 柳氮磺吡啶肠溶片人体生物等效性研究[J]. 药学实践与服务, 2013, 31(6): 424-427,466. doi: 10.3969/j.issn.1006-0111.2013.06.007

Citation:

全文HTML

参考文献 (6)

下载: 全尺寸图片幻灯片

返回文章

用微信扫码二维码

分享至好友和朋友圈

主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

电话: （021）81871324,81871397 E-mail: [email protected]

网站备案号沪ICP备05003363号-1

本系统由北京仁和汇智信息技术有限公司开发

留言板

柳氮磺吡啶肠溶片人体生物等效性研究

doi: 10.3969/j.issn.1006-0111.2013.06.007

Study on bioequivalence of sulfasalazine enteric-coated tablet in healthy volunteers

计量

出版历程

柳氮磺吡啶肠溶片人体生物等效性研究

doi: 10.3969/j.issn.1006-0111.2013.06.007

1. 第二军医大学药学院药剂学教研室, 上海 200433 2. 四川大学华西药学院, 成都 610041 3. 上海信谊药厂有限公司药物研究所, 上海 201206

English Abstract

Study on bioequivalence of sulfasalazine enteric-coated tablet in healthy volunteers

1. Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China 2. Huaxi School of Pharmacy, Sichuan University, Chengdu 610041, China 3. Institute of Drug Research, Shanghai Xinyi Pharmaceutical Co., Ltd. Shanghai 201206, China

全文HTML

目录

1. 第二军医大学药学院药剂学教研室, 上海 200433

2. 四川大学华西药学院, 成都 610041

3. 上海信谊药厂有限公司药物研究所, 上海 201206

1. Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

2. Huaxi School of Pharmacy, Sichuan University, Chengdu 610041, China

3. Institute of Drug Research, Shanghai Xinyi Pharmaceutical Co., Ltd. Shanghai 201206, China